The success of the breakthrough therapies program has stakeholders wondering whether some of its tenets could be applied more broadly.
It is a question that likely will come down to FDA's ability to handle the additional work, but given the success of the breakthrough program, there likely will be a push from industry and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?